GSK717
Based on 12 publication(s) in Google Scholar
GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 1595278-21-9
- Formula: C28H28N4O2
- Molecular Weight:452.55
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
NF-κB Signaling Compound Library
HY-L014
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Targeted Diversity Library
HY-L099
-
Chemokine Compound Library
HY-L132
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Highly Selective Inhibitors Library
HY-L158
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Pattern Recognition Receptors Library
HY-L237
Publications Citing Use of MedChemExpress (MCE) GSK717
More- Cell Host Microbe. 2026 Apr 8;34(4):672-691.e13. [Abstract]
- Cell Host Microbe. 2022 Oct 12;30(10):1435-1449.e9. [Abstract]
- Drug Resist Updat. 2023 Nov:71:101005. [Abstract]
- Nat Commun. 2026 Apr 20;17(1):5465. [Abstract]
- Nat Commun. 2025 Feb 1;16(1):1256. [Abstract]
- Redox Biol. 2026 May 14:94:104211. [Abstract]
- J Exp Clin Cancer Res. 2023 Sep 9;42(1):236. [Abstract]
- Phytomedicine. 2024 Jul 25:130:155580. [Abstract]
- mBio. 2026 Jun 10;17(6):e0084026. [Abstract]
- J Leukoc Biol. 2026 Jun 27:qiag090. [Abstract]
- Pulm Circ. 2024 Jul 3;14(3):e12379. [Abstract]
- J Stroke Cerebrovasc Dis. 2024 Jun;33(6):107689. [Abstract]
Customer Validation & Images
-
WB
-
Flow Cytometry
-
In Vivo Efficacy Study
-
ELISA
-
Histological Imaging/Staining
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | IC50 |
0.4 μM
Compound: 26, GSK717
|
Inhibition of NOD1 (unknown origin) expressed in HEK293T cells coexpressing NF-kappaB driven luciferase reporter gene by HTS primary assay
Inhibition of NOD1 (unknown origin) expressed in HEK293T cells coexpressing NF-kappaB driven luciferase reporter gene by HTS primary assay
|
[PMID: 24707857] |
GSK717 blocks synergy between NOD2 and TLR2. GSK717 does not affect NOD1, TNFR1 and TLR2-mediated responses. GSK717 (5 μM) inhibits the release of IL-8, IL-6, TNFα and IL-1β in primary human monocytes stimulated with MDP[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1595278-21-9
-
Appearance Solid
-
Molecular Weight 452.55
-
Formula C28H28N4O2
-
Color White to off-white
-
SMILES
O=C(NC1=CC=C2C(CCC2)=C1)CN3C4=CC=CC=C4N=C3CCN(C)C(C5=CC=CC=C5)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Cell Host Microbe
Gut microbiota immaturity with DL-endopeptidase deficiency links antibiotic use to preterm late-onset sepsis. [Abstract]2026 Apr 8;34(4):672-691.e13. PMID: 41763213 -
Cell Host Microbe
2022 Oct 12;30(10):1435-1449.e9. PMID: 36049483
GSK717 purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2022 Oct 12;30(10):1435-1449.e9. [Abstract]
GSK717 (10 μg/g; i.p.; 1 d). Body weight change, colon length, and intestinal barrier permeability of mice with DSS-induced colitis were indicated by FITC-dextran permeability.
GSK717 purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2022 Oct 12;30(10):1435-1449.e9. [Abstract]
GSK717 (10 μg/g; i.p.; 1 d). Levels of cytokines (TNF-a, IFN-g, IL-17, and IL-16) in serum of mice with DSS-induced colitis.
GSK717 purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2022 Oct 12;30(10):1435-1449.e9. [Abstract]
GSK717 (10 μg/g; i.p.; 1 d). Representative PCNA staining of colonic sections of mice with DSS-induced colitis.
-
Drug Resist Updat
Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer. [Abstract]2023 Nov:71:101005. PMID: 37647746
GSK717 purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2023 Nov:71:101005. [Abstract]
GSK717 (50 μM) impaired the expression of NF-κB and ABC transporters in pancreatic cancer cells.
GSK717 purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2023 Nov:71:101005. [Abstract]
GSK717 (50 μM) increased GEM-induced apoptosis of pancreatic cancer cells.
-
Nat Commun
Engineered BCG selectively triggers trained immunity in tumor-associated macrophages and sensitizes glioblastoma to radiotherapy in mice. [Abstract]2026 Apr 20;17(1):5465. PMID: 42009673 -
Nat Commun
The ubiquitin ligase Pellino1 targets STAT3 to regulate macrophage-mediated inflammation and tumor development. [Abstract]2025 Feb 1;16(1):1256. PMID: 39893188 -
Redox Biol
8-oxo-7,8-dihydroguanosine (8-oxo-Guo) drives pulmonary inflammatory pathways through pattern recognition receptors. [Abstract]2026 May 14:94:104211. PMID: 42190561 -
J Exp Clin Cancer Res
Fusobacterium nucleatum-triggered neutrophil extracellular traps facilitate colorectal carcinoma progression. [Abstract]2023 Sep 9;42(1):236. PMID: 37684625 -
Phytomedicine
Alcohol inducing macrophage M2b polarization in colitis by modulating the TRPV1-MAPK/NF-κB pathways. [Abstract]2024 Jul 25:130:155580. PMID: 38810558 -
mBio
Staphylococcal lipoproteins and peptidoglycans synergize to drive skin abscess formation. [Abstract]2026 Jun 10;17(6):e0084026. PMID: 42138419 -
J Leukoc Biol
2026 Jun 27:qiag090. PMID: 42364103 -
Pulm Circ
Human pulmonary microvascular endothelial cells respond to DAMPs from injured renal tubular cells. [Abstract]2024 Jul 3;14(3):e12379. PMID: 38962184 -
J Stroke Cerebrovasc Dis
Shikonin attenuates cerebral ischemia/reperfusion injury via inhibiting NOD2/RIP2/NF-κB-mediated microglia polarization and neuroinflammation. [Abstract]2024 Jun;33(6):107689. PMID: 38527567
Solvent & Solubility
DMSO : 250 mg/mL (552.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2097 mL | 11.0485 mL | 22.0970 mL | 55.2425 mL |
| 5 mM | 0.4419 mL | 2.2097 mL | 4.4194 mL | 11.0485 mL | |
| 10 mM | 0.2210 mL | 1.1049 mL | 2.2097 mL | 5.5243 mL | |
| 15 mM | 0.1473 mL | 0.7366 mL | 1.4731 mL | 3.6828 mL | |
| 20 mM | 0.1105 mL | 0.5524 mL | 1.1049 mL | 2.7621 mL | |
| 25 mM | 0.0884 mL | 0.4419 mL | 0.8839 mL | 2.2097 mL | |
| 30 mM | 0.0737 mL | 0.3683 mL | 0.7366 mL | 1.8414 mL | |
| 40 mM | 0.0552 mL | 0.2762 mL | 0.5524 mL | 1.3811 mL | |
| 50 mM | 0.0442 mL | 0.2210 mL | 0.4419 mL | 1.1049 mL | |
| 60 mM | 0.0368 mL | 0.1841 mL | 0.3683 mL | 0.9207 mL | |
| 80 mM | 0.0276 mL | 0.1381 mL | 0.2762 mL | 0.6905 mL | |
| 100 mM | 0.0221 mL | 0.1105 mL | 0.2210 mL | 0.5524 mL |
GSK717 Related Classifications
HY-136555 Related Classifications
Powered by Bioz